Source URL: nielsonlab.umn.edu/
1. LSD, psilocybin or MDMA for end of life anxiety
Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study
2. LSD and psilocybin for migraine and cluster headaches
Response of cluster headache to psilocybin and LSD
Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey
Psychoactive substances as a last resort—a qualitative study of self-treatment of migraine and cluster headaches
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
3. Psilocybin for depression
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study
Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Trial of Psilocybin versus Escitalopram for Depression
4. Ayahuasca for depression
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study
Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
Therapeutic potential of ayahuasca in grief: a prospective, observational study
Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial
5. Ayahuasca for addiction
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada
Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence–qualitative results.
Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans.
Short-Term Treatment Effects of a Substance Use Disorder Therapy Involving Traditional Amazonian Medicine
6. Ayahuasca for PTSD
Ayahuasca as a Candidate Therapy for PTSD
A Qualitative Assessment of Risks and Benefits of Ayahuasca for Trauma Survivors
7. Ibogaine for addiction
Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures
Noribogaine reduces nicotine self-administration in rats
Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study
Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes
8. Psilocybin for addiction
Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Psilocybin-occasioned Mystical Experiences in the Treatment of Tobacco Addiction
Long-term Follow-up of Psilocybin-facilitated Smoking Cessation
Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
9. Psilocybin for OCD
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder
Psilocybin and Obsessive Compulsive Disorder
Long-term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-containing Mushrooms
10. MDMA for PTSD
MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder
The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study
A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study
Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy
MDMA-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials
Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
11. MDMA for social anxiety in autistic adults
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
12. Cannabidiol for Dravet’s syndrome
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
13. Marijuana for PTSD
On Disruption of Fear Memory by Reconsolidation Blockade: Evidence from Cannabidiol Treatment
Δ9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption
Cannabidiol Regulation of Learned Fear: Implications for Treating Anxiety-Related Disorders
Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety‐related and substance abuse disorders
Preliminary, Open-Label, Pilot Study of Add-On Oral Δ9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder
PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program
Blunted stress reactivity in chronic cannabis users
Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults: a preliminary study
The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial
14. Ketamine for depression (in progress, many trials on this)
Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression
The Effect of Repeated Ketamine Infusion Over Facial Emotion Recognition in Treatment-Resistant Depression: A Preliminary Report
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial
Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study
Intravenous ketamine infusion for a patient with treatment‐resistant major depression: a 10‐month follow‐up
Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study
Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression
Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial.
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study
Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial
15. Ketamine for PTSD
Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic
Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study
Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder
16. MDMA for addiction
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder
17. Ketamine for addiction
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial
Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories
